pc 버전으로 이동 중 [시장보고서]세계의 바이오의약품 첨가제 제조 시장 : 생물제제 유형별(항체, 백신, 세포치료, 기타 생물제제), 첨가제 유형별(당질, 폴리머, 가용화제/계면활성제)
세계의 바이오의약품 첨가제 제조 시장 : 생물제제 유형별(항체, 백신, 세포치료, 기타 생물제제), 첨가제 유형별(당질, 폴리머, 가용화제/계면활성제)
Biopharmaceutical Excipient Manufacturing Market by Type of Biologics (Antibodies, Vaccines, Cell Therapies and Other Biologics), Type of Excipient (Carbohydrates, Polymers, Solubilizers / Surfactants,
상품코드 : 1063798
리서치사 : Roots Analysis
발행일 : 2022년 01월
페이지 정보 : 영문 175 Pages
US $ 5,899 ₩ 7,340,000
PDF (Single User License)
US $ 7,999 ₩ 9,953,000
PDF (Site License)
US $ 10,599 ₩ 13,189,000
PDF (Department License)
US $ 17,999 ₩ 22,397,000
PDF (Enterprise License)


한글목차

세계의 생물제제 시장은 향후 몇 년간 지속적이고 안정적으로 성장할 것으로 예상됩니다. 그러나, 생물학적 치료제는 저분자 의약품에 비해 본질적으로 안정성이 부족하기 때문에 약리학적으로 불활성 물질인 다양한 첨가제가 사용되고 있습니다. 또 첨가제는 원료의약품(API)의 용해도와 생체이용률을 높여 pH와 긴장성을 제어함으로써 생물제제 개발에서 중요한 역할을 하고 있습니다. 또한 바이오의약품 첨가제는 팽창제, 산화방지제, 방부제로서의 기능도 합니다. 그래서 바이오의약품 첨가제 수요는 크게 증가하고 있습니다.

세계의 바이오의약품 첨가제(Biopharmaceutical Excipient) 제조 시장을 분석했으며, 시장의 기본 구조와 최신 상황, 주요 사업 제휴 및 협력이나 규모 확장 움직여, 주요 기업 개요, 전체적인 시장 규모 동향 전망, 부문별·지역별 상세 동향 등의 정보를 정리하여 전해드립니다.

본문 내 도표 샘플

목차

제1장 서론

제2장 개요

제3장 서론

제4장 시장 구도

제5장 기업 경쟁력 분석

제6장 기업 개요 개요 : 바이오의약품 첨가제 제조업체

제7장 사업 제휴 및 협력

제8장 최근 확장

제9장 용량 분석

제10장 시장 예측과 기회 분석

제11장 결론

제12장 주요 인사이트

제13장 부록 1 : 집계 데이터

제14장 부록 2 : 기업 및 조직 리스트

LSH 22.03.31
영문 목차

영문목차

Title:
Biopharmaceutical Excipient Manufacturing
Market by Type of Biologics (Antibodies, Vaccines, Cell Therapies and Other Biologics), Type of Excipient (Carbohydrates, Polymers, Solubilizers / Surfactants, Polyols, Proteins / Amino Acids and Others, Company Size (Small, Mid-sized, Large / Very Large), Scale of Operation (Preclinical, Clinical and Commercial) and Key Geographies (North America, Europe, Asia Pacific, Latin America, MENA, and RoW): Industry Trends and Global Forecasts, 2022-2035.

Example Insights:

Overview:

Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. In fact, over 8,000 biological pharmaceutical products are currently under clinical investigation worldwide. Given the evident benefits of biologics over small molecule drugs (including high efficacy, target specificity and favorable safety profiles), the biopharmaceutical market is poised to witness continued and consistent growth over the next several years. However, biological therapeutics are inherently less stable than small molecules and, hence, more prone to degradation by several physical and chemical degradation mechanisms. Therefore, a variety of excipients, which are pharmacologically inert substances themselves, are used to stabilize biologics during the manufacturing process and storage. Furthermore, excipients play a critical role in biologics development by enhancing the solubility and bioavailability, controlling pH and tonicity of the active pharmaceutical ingredients (APIs). Additionally, biopharmaceutical excipients act as bulking agents, antioxidants or preservatives. As a result, the demand for biopharmaceutical excipients has grown considerably. However, for some of the biopharmaceutical excipients, such as lipids, the associated manufacturing processes are highly complex, capital-intensive and fraught with multiple challenges. Some of the major issues related to the production of GMP grade biopharmaceutical excipients include the need for specialized expertise, lack of facilities with the necessary infrastructure and capacity to produce the required quality of substances, as well as concerns related to storage, safety and efficacy.

Considering the technical and routine operations-related challenges, an increasing number of biologics developers are increasingly relying on biopharmaceutical excipient manufacturers. The benefits of engaging such third-party service providers are numerous; for instance, contracting a supplier for medical grade biopharmaceutical excipients enables sponsors to leverage specialty biopharmaceutical excipients (available with the manufacturers), access larger capacities and achieve greater operational flexibility. Presently, there are several contract manufacturers that claim to have the required capabilities to manufacture a variety of biopharmaceutical excipients, including lipids, lactose, trehalose, mannitol, succinate, Tween 20 and benzyl alcohol. These companies are increasingly focusing on the development of co-processed multifunctional biopharmaceutical excipients to improve the stability and effectiveness of novel biotherapeutics. It is worth highlighting that biopharmaceutical excipient manufacturers are actively trying to consolidate their presence in this field by entering into strategic alliances, enhance their respective manufacturing capabilities in order to meet the growing demand for excipients used in biologics. In fact, recently, a number of deals were inked between vaccine developers and biopharmaceutical excipient manufacturers in order to cater to the urgent need for lipids for the formers' respective COVID-19 vaccines. With outsourcing being increasingly accepted as a viable and beneficial business model within this field, we anticipate the biopharmaceutical excipient manufacturing market to grow at a steady pace in the coming years.

Scope of the Report:

The 'Biopharmaceutical Excipient Manufacturing Market by Type of Biologics (Antibodies, Vaccines, Cell Therapies and Other Biologics), Type of Excipient (Carbohydrates, Polymers, Solubilizers / Surfactants, Polyols, Proteins / Amino Acids and Others, Company Size (Small, Mid-sized, Large / Very Large), Scale of Operation (Preclinical, Clinical and Commercial) and Key Geographies (North America, Europe, Asia Pacific, Latin America, MENA, and RoW): Industry Trends and Global Forecasts, 2022-2035' report features an extensive study of companies engaged in manufacturing of biopharmaceutical excipients. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features:

One of the key objectives of the report was to evaluate the current opportunity and the future potential of the biopharmaceutical excipient manufacturing market, over the next 15 years. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] type of biologics (antibodies, vaccines, cell therapies and other biologics), [B] type of excipient (carbohydrates, polymers, solubilizers / surfactants, polyols, proteins / amino acids and others), [C] company size (small, mid-sized, large / very large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world).

In order to account for future uncertainties in the market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

Key Questions Answered:

Chapter Outlines:

Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the likely evolution of the biopharmaceutical excipient manufacturing market in the short to mid-term, and long term.

Chapter 3 provides a general overview of the biopharmaceutical excipients. In addition, it includes information on their properties and classification, based on route of administration, chemical structure, function, ability to interfere with metabolization and efflux mechanisms. Further, it highlights various applications of biopharmaceutical excipients and their role in pharmaceutical and biopharmaceutical industry.

Chapter 4 provides an overview of the current biopharmaceutical excipients, along with information on their year of establishment, company size (in terms of employee count), location of headquarters, location of manufacturing facilities, type of excipient (based on chemical composition (carbohydrates, polyols, polymers, proteins / amino acids, salts, lipids, and others), based on function (surfactants, stabilizers, tonicity modifiers, bulking agents, buffering agents, solubility enhancers, drug delivery system, chelators, antimicrobials, antioxidants and others), based on chemical structure (organic and inorganic)), scale of operation (preclinical, clinical and commercial), type of formulation (liquid or parenteral and solid), type of biologic (vaccines, proteins / peptides, cell therapies, antibodies and blood products) and global regulatory compliance (United States Pharmacopoeia / United States Pharmacopoeia-National Formulary, European Pharmacopoeia, Japanese Pharmacopoeia, British Pharmacopoeia, China Pharmacopoeia, American Chemical Society grade, Indian Pharmacopoeia, Food Chemical Codex and Taiwan FDA).

Chapter 5 features a detailed competitiveness analysis of the biopharmaceutical excipient manufacturers, based on supplier power (in terms of years of experience), company competitiveness (type of excipient based on chemical composition, function, chemical structure, and based on scale of operation, type of formulation, type of biologic, global regulatory compliance) and number of manufacturing facilities.

Chapter 6 provides detailed profiles of prominent players (shortlisted based on a proprietary criterion) engaged in this domain. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), details related to its biopharmaceutical excipients portfolio, manufacturing facilities, recent developments, and an informed future outlook.

Chapter 7 features an analysis of the various collaborations and partnerships inked between stakeholders engaged in this domain, during the period 2016-2021, covering distribution agreements, acquisitions, supply agreements, product development agreements, asset acquisitions, research and development agreements, manufacturing agreements, service alliances and other related agreements.

Chapter 8 presents a detailed analysis of the recent expansions undertaken by various biopharmaceutical excipient manufacturers, based on several relevant parameters, such as year of expansion, type of expansion (capacity expansion, facility expansion and new facility), company size (small, mid-sized, large and very large companies), location of headquarters, location of expanded facility, type of excipient, type of drug molecule, most active players (in terms of number of recent expansions) and geographical distribution (region-wise and country-wise).

Chapter 9 features a comprehensive analysis of the global installed capacity for biopharmaceutical excipients taking into consideration the capacities of various biopharmaceutical excipient manufacturers, along with information on the distribution of available global biopharmaceutical excipient production capacity based on several relevant parameters, such as company size (small, mid-sized, large and very large companies), scale of operation (preclinical, clinical and commercial) and key geographical regions (North America, Europe, and Asia-Pacific).

Chapter 10 presents an insightful market forecast analysis, highlighting the likely growth of the biopharmaceutical excipient manufacturing market till the year 2035. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of biologic (antibodies, vaccines, cell therapies and other biologics), [B] type of excipient (carbohydrates, polymers, solubilizers / surfactants, polyols, proteins / amino acids and others), [C] company size (small, mid-sized, large / very large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world).

Chapter 11 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 12 provides the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the biopharmaceutical excipient manufacturing domain.

Chapter 13 is an appendix, that provides tabulated data and numbers for all the figures included in the report.

Chapter 14 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

Table of Contents

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET LANDSCAPE

5. COMPANY COMPETITIVENESS ANALYSIS

6. COMPANY PROFILES: BIOPHARMACEUTICAL EXCIPIENT MANUFACTURERS

7. PARTNERSHIPS AND COLLABORATIONS

8. RECENT EXPANSIONS

9. CAPACITY ANALYSIS

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS

11. CONCLUDING REMARKS

12. EXECUTIVE INSIGHTS

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기